Paul J. Lytle
2016
In 2016, Paul J. Lytle earned a total compensation of $755K as Chief Financial Officer at Peregrine Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $156,000 |
|---|---|
| Option Awards | $158,430 |
| Salary | $390,000 |
| Other | $50,580 |
| Total | $755,010 |
Lytle received $390K in salary, accounting for 52% of the total pay in 2016.
Lytle also received $156K in non-equity incentive plan, $158.4K in option awards and $50.6K in other compensation.
Rankings
In 2016, Paul J. Lytle's compensation ranked 9,534th out of 14,075 executives tracked by ExecPay. In other words, Lytle earned more than 32.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,534 out of 14,075 | 32nd |
Division Manufacturing | 3,692 out of 5,489 | 33rd |
Major group Chemicals And Allied Products | 1,282 out of 1,895 | 32nd |
Industry group Drugs | 1,018 out of 1,538 | 34th |
Industry Pharmaceutical Preparations | 802 out of 1,176 | 32nd |
Source: SEC filing on August 17, 2018.
Lytle's colleagues
We found three more compensation records of executives who worked with Paul J. Lytle at Peregrine Pharmaceuticals in 2016.